4/1/2024 | BK | United Therapeutics extends revolver by one year to 2029
|
3/31/2023 | BK | United Therapeutics extends revolver by one year to 2028
|
4/22/2022 | SP | New Issue: GS Finance sells $8 million basket-linked notes tied to 45 stocks
|
4/1/2022 | BK | United Therapeutics inks new five-year revolvers for $2 billion
|
12/2/2020 | BK | United Therapeutics extends revolving credit facility to 2025
|
6/28/2019 | BK | United Therapeutics extends $1.5 billion revolving facility by one year
|
6/28/2018 | BK | United Therapeutics closes $1.5 billion revolving credit agreement
|
1/30/2018 | BK | United Therapeutics extends revolver maturity by one year to 2023
|
1/30/2017 | BK | United Therapeutics extends $1 billion revolver’s maturity to 2022
|
4/28/2016 | PP | Market Commentary: Xilinx slides as outlook disappoints; energy names continue to outperform; Chesapeake up
|
4/28/2016 | CV | Market Commentary: Xilinx slides as outlook disappoints; energy names continue to outperform; Chesapeake up
|
2/1/2016 | BK | United Therapeutics enters into $1 billion revolving credit agreement
|
1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
12/23/2013 | CV | Market Commentary: United Therapeutics jumps outright, 'comes in' on hedge; Navistar 3% tracks with shares
|
12/23/2013 | CV | Market Commentary: Midday Commentary: United Therapeutics jumps outright with shares; Navistar 3% tracks with shares
|
10/29/2013 | CV | United Therapeutics' holders may convert 1% convertible senior notes
|
9/30/2013 | BK | United Therapeutics enters into $75 million revolving credit facility
|
3/25/2013 | CV | Market Commentary: Holidays, vacations result in subdued marketplace; Suntech notes jump in late-day trading
|
2/14/2013 | CV | Market Commentary: AMR rallies on merger agreement; Coinstar 'comes in;' planned Cliffs upsized, talk tightened
|
7/26/2012 | CV | Market Commentary: United Therapeutics gains on hedge after earnings; Cash America down outright, up on hedge
|
12/30/2011 | CV | Outlook 2012: Convertibles primary market set for weakness without higher rates, stronger economy
|
11/2/2011 | CV | Market Commentary: Human Genome's new $430 million deal prices at 99, edges higher; MF Global adds a little
|
10/13/2011 | CV | Market Commentary: Clearwire extends gains on positive quarterly figures; United Therapeutics paper unchanged
|
10/12/2011 | CV | New Issue: United Therapeutics sells $250 million five-year convertibles to yield 1%, up 20%
|
10/12/2011 | CV | Market Commentary: United Therapeutics prices new issue; EarthLink to redeem 3.25% convertibles; market gains
|
10/11/2011 | CV | Market Commentary: Convertibles 'better to buy'; New issue market welcomes new United Therapeutics paper
|
10/11/2011 | CV | United Therapeutics to sell $210 million five-year convertible notes at 0.5%-1%, up 20%-25%
|
8/25/2011 | CV | Market Commentary: Sellers push Suntech Power lower; United Therapeutics retains gain; Bank of America adds
|
8/24/2011 | CV | Market Commentary: Hedge players win on United Therapeutics; Amerigroup adds; investment-grade paper active
|
4/6/2010 | CV | Market Commentary: Telvent prices at the cheaps for the yield; Massey Energy contracts on mine blast disaster
|
11/17/2008 | PP | New Issue: United Therapeutics to sell $150 million placement of shares
|
11/17/2008 | PP | Market Commentary: United Therapeutics lands $150 million partnership; Level 3 funds buybacks; Cleanfield, Ontex offer stock
|
11/16/2007 | CV | Defensive convertibles provide safety in a volatile market, Lehman Brothers report says
|
11/1/2007 | CV | Market Commentary: Successful test spurs United Therapeutics; iStar, Countrywide down with financials; tough day for four new issues
|
10/31/2006 | BT | United Therapeutics Q3 revenues up 22%, net income drops to $8.5 million
|
10/30/2006 | BTCV | United Therapeutics greenshoe fully exercised, raising convertibles issue to $250 million
|
10/25/2006 | CV | Market Commentary: ImClone slips on board change; Mills gains on offer; United Therapeutics improves; GM slips
|
10/24/2006 | BT | Market Commentary: United Therapeutics climbs 9%; Vanda gains to another new high; Titan flat; Critical retreats by 8%
|
10/24/2006 | CV | Market Commentary: JetBlue climbs on trimmed expansion; Lucent gains on results; United Therapeutics prices deal; L-3 slips
|
10/24/2006 | BTCV | New Issue: United Therapeutics prices $210 million convertibles near cheap end, at 0.5%, up 21%
|
10/23/2006 | CV | Market Commentary: Connetics soars on buyout; Ford slips; FiberTower could see tough borrow; United Therapeutics plans deal
|
10/23/2006 | BTCV | United Therapeutics to price $210 million five-year convertibles, talked at 0%-0.5%, up 20%-24%
|
8/1/2006 | BT | United Therapeutics reports second quarter income of $7.7 million
|
7/27/2006 | BT | United Therapeutics repurchases Toray common stock
|
6/20/2006 | BT | United Therapeutics' OvaRex phase 3 trials fully enrolled
|
6/13/2006 | BT | Supernus, United Therapeutics form partnership to develop UT-15C for hypertension
|
6/12/2006 | BT | Lung Rx to expand Triumph study
|
3/21/2006 | BT | United Therapeutics announces FDA approval of sNDA for Remodulin Injection
|
12/19/2005 | BT | United's Remodulin improves walk distance in hypertension study
|
12/12/2005 | BT | United Therapeutics completes enrollment in first of two phase 3 trials of OvaRex for ovarian cancer
|
8/2/2005 | BT | Market Commentary: Anadys up on Novartis details; Ariad, Nastech, ZymoGenetics mixed; Myogen zooms; Isis gains
|